A case report of fatal anaphylaxis on first exposure to rasburicase just before lymphoma treatment
Abstract Background Rasburicase, a recombinant urate oxidase enzyme, has potent efficacy in controlling uric acid and is widely used to prevent tumor lysis syndrome in high-risk patients owing to its low toxicity profile. However, it has been associated with a risk of anaphylaxis, especially on re-e...
Saved in:
| Main Authors: | Yoshikazu Utsu, Natsuho Kaneda, Makio Kawakami, Shin-ichi Masuda, Hironori Arai, Sonoko Shimoji, Rena Matsumoto, Takafumi Tsushima, Kazusuke Tanaka, Kosuke Matsuo, Chiharu Kimeda, Shiho Konno, Nobuyuki Aotsuka |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-10-01
|
| Series: | Allergy, Asthma & Clinical Immunology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13223-024-00920-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of a reduced-dose rasburicase: Single-institution experience in India
by: K C Lakshmaiah, et al.
Published: (2019-01-01) -
A case report of newly diagnosed epithelial ovarian carcinoma presenting with spontaneous tumor lysis syndrome and its successful management with rasburicase
by: Deepak Kumar Shukla, et al.
Published: (2017-01-01) -
Anaphylaxis in family practice
by: Walter Kloeck
Published: (2008-02-01) -
Anaphylaxis
by: Elissa M. Abrams, et al.
Published: (2024-12-01) -
Therapy in alergy and anaphylaxis
by: Cristina, T. Romeo
Published: (2008-06-01)